Perspective Therapeutics Correlations
CATX Stock | 2.52 0.03 1.20% |
The current 90-days correlation between Perspective Therapeutics and Sight Sciences is 0.14 (i.e., Average diversification). The correlation of Perspective Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Perspective Therapeutics Correlation With Market
Very weak diversification
The correlation between Perspective Therapeutics and DJI is 0.41 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Perspective Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Perspective |
Moving together with Perspective Stock
0.81 | HOLX | Hologic | PairCorr |
0.71 | INFU | InfuSystems Holdings | PairCorr |
0.66 | SSKN | STRATA Skin Sciences Earnings Call Today | PairCorr |
0.74 | ELEV | Elevation Oncology | PairCorr |
0.8 | GPCR | Structure Therapeutics | PairCorr |
0.79 | ZVSA | ZyVersa Therapeutics | PairCorr |
0.66 | IMMX | Immix Biopharma | PairCorr |
0.77 | IMRX | Immuneering Corp | PairCorr |
0.65 | KRON | Kronos Bio | PairCorr |
0.85 | PYXS | Pyxis Oncology | PairCorr |
0.62 | RAIN | Rain Enhancement Tec | PairCorr |
0.79 | SCLX | Scilex Holding | PairCorr |
0.76 | ASMB | Assembly Biosciences Earnings Call Tomorrow | PairCorr |
Moving against Perspective Stock
0.81 | OCX | OncoCyte Corp | PairCorr |
0.73 | LUCD | Lucid Diagnostics | PairCorr |
0.64 | GOSS | Gossamer Bio | PairCorr |
0.62 | MNDR | Mobile health Network | PairCorr |
0.48 | PAVM | PAVmed Inc | PairCorr |
0.48 | NVCT | Nuvectis Pharma | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Perspective Stock performing well and Perspective Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Perspective Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
KIDS | 1.90 | 0.23 | 0.11 | 0.22 | 1.98 | 3.54 | 15.28 | |||
OFIX | 1.23 | (0.08) | 0.00 | (0.13) | 0.00 | 2.18 | 6.60 | |||
SGHT | 3.39 | (0.12) | 0.00 | (0.14) | 0.00 | 7.19 | 24.66 | |||
NPCE | 3.17 | 0.20 | 0.06 | 2.38 | 3.79 | 5.89 | 17.98 | |||
CVRX | 3.08 | 0.05 | 0.01 | (0.01) | 3.82 | 5.58 | 14.59 | |||
PAVM | 3.91 | 0.35 | 0.08 | 0.19 | 3.71 | 12.07 | 27.49 | |||
OSA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
HYPR | 5.23 | 0.07 | 0.01 | (0.12) | 8.05 | 11.36 | 68.04 | |||
ELMD | 2.31 | (0.15) | 0.00 | (0.18) | 0.00 | 3.90 | 21.31 | |||
SRDX | 1.51 | (0.38) | 0.00 | (0.67) | 0.00 | 2.15 | 10.84 |
Perspective Therapeutics Corporate Management
Annie Cheng | Vice Relations | Profile | |
Andrew Bright | Executive Brachytherapy | Profile | |
Michael Schultz | Chief Officer | Profile | |
Steve Keefe | Senior Development | Profile | |
PGradDip BA | Chief Officer | Profile | |
Jonathan Hunt | Chief Officer | Profile |